SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 99.50 |
| Enterprise Value ($M) | 82.33 |
| Book Value ($M) | 10.99 |
| Book Value / Share | 0.57 |
| Price / Book | 9.05 |
| NCAV ($M) | 10.99 |
| NCAV / Share | 0.57 |
| Price / NCAV | 9.05 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.76 |
| Return on Assets (ROA) | -0.87 |
| Return on Equity (ROE) | -1.16 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.74 |
| Current Ratio | 2.74 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 17.31 |
| Assets | 17.31 |
| Liabilities | 6.32 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Pontifax Management 4 G.p. (2015) Ltd. | 1.50 | -68.51 | |
| 13G/A | Mosseri Marlio Charles | 15.00 | 9.03 | |
| 13G/A | Shemesh Shay | 8.60 | 23.72 | |
| 13G/A | Poradosu Enrique | 8.70 | 23.43 | |
| 13G/A | Peters Thomas Phineas | 5.20 | -4.13 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 21,550 | 68,406 | 31.50 | |
| 20,531 | 57,553 | 35.67 | |
| 14,868 | 67,311 | 22.09 | |
| 40,837 | 168,094 | 24.29 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NRBO – NeuroBo Pharmaceuticals, Inc. | NRSN – NeuroSense Therapeutics Ltd. |
| NRXP – NRx Pharmaceuticals, Inc. | OCEA – Ocean Biomedical, Inc. |
| OCGN – Ocugen, Inc. |
Financial data and stock pages provided by
Fintel.io